BEAM - Beam Therapeutics Inc.
IEX Last Trade
28.83
3.340 11.585%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:18:32 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$25.49
3.34
13.10%
Fundamental analysis
12%
Profitability
0%
Dept financing
10%
Liquidity
75%
Performance
10%
Performance
5 Days
-0.69%
1 Month
8.11%
3 Months
17.59%
6 Months
18.80%
1 Year
-2.27%
2 Year
-24.34%
Key data
Stock price
$28.83
DAY RANGE
$25.49 - $28.92
52 WEEK RANGE
$21.90 - $49.50
52 WEEK CHANGE
-$0.93
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: John Evans
Region: US
Website: beamtx.com
Employees: 510
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: beamtx.com
Employees: 510
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Beam Therapeutics Inc. develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders.
Recent news